Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

[1]  M. Lawrence,et al.  Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer , 2021, Clinical Cancer Research.

[2]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  R. Riedel,et al.  Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program , 2021, Therapeutic advances in medical oncology.

[4]  A. Shaw,et al.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. , 2020, The New England journal of medicine.

[5]  A. Valipour,et al.  Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis , 2020, Pharmaceuticals.

[6]  R. Wanchoo,et al.  Lorlatinib induced proteinuria: A case report , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[7]  N. Syn,et al.  An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  A. Drilon,et al.  Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[9]  G. Ferretti,et al.  Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. , 2019 .

[10]  A. Shaw,et al.  Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. , 2019, The Lancet. Oncology.

[11]  G. Ferretti,et al.  Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  S. C. Wang,et al.  Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. , 2019 .

[13]  M. Hellmich,et al.  Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  Jen-Chin Wang,et al.  Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature , 2018, Journal of Medical Case Reports.

[15]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Ahn,et al.  Characteristics and Outcome of ROS1‐Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  J. V. van Putten,et al.  Effects of crizotinib on creatinine clearance and renal hemodynamics. , 2018, Lung cancer.

[18]  Kenneth L. Jones,et al.  Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer , 2018, Clinical Cancer Research.

[19]  Taichi Murakami,et al.  Progressive renal insufficiency related to ALK inhibitor, alectinib , 2018, Oxford medical case reports.

[20]  A. Iafrate,et al.  Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. , 2017, JCO precision oncology.

[21]  M. Ahn,et al.  Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Roman K. Thomas,et al.  Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. McTigue,et al.  PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations , 2015, Proceedings of the National Academy of Sciences.

[24]  F. Cappuzzo,et al.  Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[25]  Jeffrey W. Clark,et al.  ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Tsao,et al.  ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .